Impact of Post-Progression Therapy (PPT) on Survival in AVF2107, a phase III trial of bevacizumab (AVASTIN™) in the first-line treatment of metastatic colorectal cancer

被引：0
|
作者：
Hedrick, Eric [1 ]
Hurwitz, H. [2 ]
Sarkar, S.
Griffing, S.
Grothey, A. [3 ]
机构：
[1] Genentech Inc, Hematol Oncol, Summit, NJ USA
[2] Duke Univ, Durham, NC USA
[3] Mayo Clin, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC).
    Hedrick, EE
    Hurwitz, H
    Sarkar, S
    Griffing, S
    Novotny, W
    Grothey, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 249S - 249S
  • [2] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [3] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [4] Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer
    Shimokawa, M.
    Ohki, M.
    Kaku, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (04) : 370 - 375
  • [5] CORRELATION OF PROGRESSION-FREE AND POST-PROGRESSION SURVIVAL WITH OVERALL SURVIVAL IN PHASE III TRIALS OF FIRST-LINE CHEMOTHERAPY FOR ADVANCED EPITHELIAL OVARIAN CANCER
    Shimokawa, M.
    Ohki, M.
    Kaku, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 393 - 393
  • [6] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [7] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [8] Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
    Martin, Miguel
    Loibl, Sibylle
    von Minckwitz, Gunter
    Morales, Serafin
    Martinez, Noelia
    Guerrero, Angel
    Anton, Antonio
    Aktas, Bahriye
    Schoenegg, Winfried
    Munoz, Montserrat
    Angel Garcia-Saenz, Jose
    Gil, Miguel
    Ramos, Manuel
    Margeli, Mireia
    Carrasco, Eva
    Liedtke, Cornelia
    Wachsmann, Grischa
    Mehta, Keyur
    De la Haba-Rodriguez, Juan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1045 - +
  • [9] Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
    Robertson, Jane D.
    Botwood, Nick A.
    Rothenberg, Mace L.
    Schmoll, Hans-Joachim
    CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 59 - 60
  • [10] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
12345